ASCO 2023 | Nipavect: niraparib and panitumumab in RAS-wild type colorectal cancer

Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, gives an overview of the Phase II Nipavect trial (NCT03983993) of niraparib, a PARP inhibitor, and panitumumab, an EGFR inhibitor, in advanced RAS-wild type colorectal cancer (CRC). The investigation regimen had an acceptable safety profile, and demonstrated encouraging efficacy in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.